Rigel Pharmaceuticals, Inc. (RIGL)
After hours:
| Previous close | 9.53 |
| Open | 9.29 |
| Bid | 7.31 x 100 |
| Ask | 9.63 x 100 |
| Day's range | 8.22 - 9.65 |
| 52-week range | 7.10 - 17.30 |
| Volume | |
| Avg. volume | 200,813 |
| Market cap | 144.329M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.10 |
| Earnings date | 30 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 42.83 |
Simply Wall St.Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Rigel Pharmaceuticals, Inc.'s ( NASDAQ:RIGL ) business as it appears the...
PR NewswireRigel Announces Reverse Stock Split
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10 (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024. The company's common stock will begin trading on a post-split basis on The Nasdaq Global Select Market under the same symbol (RIGL) when the market opens on Thursday, June 27, 2024, with the new CUSIP number 766559702.
- PR Newswire
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO® (pralsetinib) for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by a U.S. Food and Drug Administration (FDA) approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid canc
